Summary
Recent advances in recombinant DNA technology have greatly expanded the number of approaches to developing safe and effective vaccines, including those for the herpes simplex virus (HSV). The current focus of clinical evaluation is on HSV subunit glycoprotein vaccines, although it is uncertain if these represent the optimal immunogens for inclusion in vaccines or whether the addition of other proteins would enhance efficacy. Similarly, the optimal adjuvants for formulation with subunit vaccines have yet to be defined. Other approaches that allow viral proteins to be synthesised within cells offer certain advantages and could lead to the vaccines of choice, although many questions remain regarding these strategies.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
References
Nahmias AJ, Lee FK, Beckman-Nahmias S. Sero-epidemiological and -sociological patterns of herpes simplex virus infection in the world. Scand J Infect Dis 1990; Suppl. 69: 19–36
Committee on Issues and Priorities for New Vaccine Development. Appendix I: prospects for immunizing against herpes simplex viruses 1 and 2. In: New vaccine development: establishing priorities. Washington: National Academy Press, 1985: 280–312
Stanberry LR. Herpes simplex virus vaccines. Semin Pediatr Infect Dis 1991; 2(3): 178–85
Burke RL. Current developments in herpes simplex virus vaccines. Semin Virol 1993; 4: 187–97
Allen WP, Hitchcock PJ, editors. Herpes simplex virus vaccine workshop. Rev Infect Dis 1991; 13: S891–979
Whitley RJ. Prospects for vaccination against herpes simplex virus. Pediatr Ann 1993; 22: 726–32
Cantin EM, Eberle R, Baidick J, et al. Expression of herpes simplex virus 1 glycoprotein B by a recombinant vaccinia virus and protection of mice against lethal HSV-1 challenge. Proc Natl Acad Sci USA 1987; 80: 7155–9
Cremer KJ, Mackett M, Wohlengerg C, et al. Vaccinia virus recombinant expressing herpes simplex virus type 1 glycoprotein D prevents latent herpes in mice. Science 1985; 228: 737–40
Paoletti E, Lipinskas BP, Samsonoff C, et al. Construction of live vaccines using genetically engineered poxviruses: biological activity of vaccinia virus recombinants expressing the hepatitis B virus surface antigen and the herpes simplex virus glycoprotein D. Proc Natl Acad Sci USA 1984; 81: 193–7
McDermott MR, Graham FL, Hanke T, et al. Protection of mice against lethal challenge with herpes simplex virus by vaccination with an adenovirus vector expressing HSV glycoprotein B. Virology 1989; 169: 244–7
Baxby D, Paoletti E. Potential use of non-replicating vectors as recombinant vaccines. Vaccine 1992; 10: 8–9
Gallichan WS, Johnson DC, Graham FL, et al. Mucosal immunity and protection after intranasal immunization with recombinant adenovirus expressing herpes simplex virus glycoprotein B. J Infect Dis 1993; 168: 622–9
Stanberry LR, Bernstein DI, Kit S, et al. Genital reinfection after recovery from initial genital infection with herpes simplex virus type 2 in guinea pigs. J Infect Dis 1986; 153: 1055–61
Thompson RL, Nakashizuka M, Stevens JG. Vaccine potential of a live avirulent herpes simplex virus. Microb Pathogen 1986; 1: 409–16
Anderson CA, August MJ, Hsiung GD. Pathogenicity of wild-type and temperature-sensitive mutants of herpes simplex virus type 2 in guinea pigs. Infect Immun 1980; 30: 159–69
Roizman B, Warren J, Thuning CA, et al. Application of molecular genetics to the design of live herpes simplex virus vaccines. Dev Biol Stand 1982; 52: 287–304
Meignier B, Longnecker R, Roizman B. In vivo behavior of genetically engineered herpes simplex viruses R7017 and R7020: construction and evaluation in rodents. J Infect Dis 1988; 158: 602–13
Meignier B, Martin B, Whitley RJ, et al. In vivo behavior of genetically engineered herpes simplex viruses R7017 and R7020: II. Studies in immunocompetent and immunosuppressed owl monkeys (Aotus trivirgatus). J Infect Dis 1990; 162: 313–21
Cadoz M, Micoud M, Seigneurin JM, et al. Phase I trial of R7020: a live attenuated recombinant herpes simplex virus (HSV) candidate vaccine [abstract No. 341]. Proceedings of the 32nd Interscience Conference on Antimicrobial Agents and Chemotherapy; 1992; Anaheim: 167
Whitley RJ, Kern ER, Chatterjee S, et al. Replication, establishment of latency and induced reactivation of herpes simplex virus γ1 34.5 deletion mutants in rodent models. J Clin Invest 1993; 91: 2837–43
Forrester A, Farrell H, Wilkinson G, et al. Construction and properties of a mutant of herpes simplex virus type 1 with glycoprotein gH sequences deleted. J Virol 1992; 66: 341–8
Nguyen LH, Knipe DM, Finbert RW. Replication-defective mutants of herpes simplex virus (HSV) induce cellular immunity and protect against lethal HSV infection. J Virol 1992; 66: 7067–72
Morrison LA, Knipe DM. Immunization with replication-defective mutants of herpes simplex virus type 1: sites of immune intervention in pathogenesis of challenge virus infection. J Virol 1994; 68: 689–96
Farrell HE, McLean CS, Harley C, et al. Vaccine potential of a herpes simplex virus type 1 mutant with an essential glycoprotein deleted. J Virol 1994; 68: 927–32
Mertz GJ, Peterman G, Ashley R, et al. Herpes simplex virus type 2 glycoprotein-subunit vaccine: tolerance and humoral and cellular responses in humans. J Infect Dis 1984; 150: 242–9
Zarling JM, Moran PA, Brewer L, et al. Herpes simplex virus (HSV)-specific proliferative and cytotoxic T-cell responses in humans immunized with an HSV-2 glycoprotein subunit vaccine. J Virol 1988; 62: 4481–5
Mertz GJ, Ashley R, Burke RL, et al. Double-blind, placebo-controlled trial of a herpes simplex virus type 2 glycoprotein vaccine in persons at high risk for genital herpes infection. J Infect Dis 1990; 161: 653–60
Frenkel LM, Dillon M, Garratty E, et al. A randomized double-blind, placebo-controlled phase I trial of a herpes simplex virus purified glycoprotein (gD1) vaccine [abstract No. 721]. Proceedings of the 29th Interscience Conference on Antimicrobial Agents and Chemotherapy; 1990; Washington: 206
Watson RJ, Weis JH, Salstrom JS, et al. Herpes simplex virus type-1 glycoprotein D gene: nucleotide sequence and expression in Escherichia coli. Science 1982; 218: 381–4
Berman PW, Gregory T, Crase D, et al. Protection from genital herpes simplex virus type 2 infection by vaccination with cloned type 1 glycoprotein D. Science 1985; 227: 1490–1
Stanberry LR, Bernstein DI, Burke RL, et al. Vaccination with recombinant herpes simplex virus glycoproteins: protection against initial and recurrent genital herpes. J Infect Dis 1987; 155: 914–20
Sanchez-Pescador L, Burke RL, Ott G, et al. The effect of adjuvants on the efficacy of a recombinant herpes simplex virus glycoprotein vaccine. J Immunol 1988; 141: 1720–7
Weinberg A, Merrigan TC. Recombinant interleukin-2 as an adjuvant for vaccine-induced protective immunisation of guinea pigs with herpes simplex virus subunit vaccines. J Immunol 1988; 140: 294–9
Hazama M, Mayani-Aono A, Asakawa N, et al. Adjuvant-independent enhanced immune response to recombinant herpes simplex virus type 1 glycoprotein D by fusion with biologically active interleukin-2. Vaccine 1993; 11: 629–36
Straus SE, Savarese B, Tigges M, et al. Induction and enhancement of immune responses to herpes simplex virus type 2 in humans by use of a recombinant glycoprotein D vaccine. J Infect Dis 1993; 167: 1045–52
Leroux-Roels G, Moreau E, Verhasselt B. Immunogenicity and reactogenicity of recombinant herpes simplex virus type-2 (HSV-2) glycoprotein D vaccine with monophosphoryl lipid A in HSV-seronegative and seropositive subjects [abstract no. 1209]. Proceedings of the 32nd Interscience Conference on Antimicrobial Agents and Chemotherapy; 1993; New Orleans: 64
Ulmer JB, Donnelly JJ, Parker SE, et al. Heterologous protection against influenza by injection of DNA encoding a viral protein. Science 1993; 259: 1745–9
Lazer MP. Vaccination for recurrent herpes simplex infection: initiation of a new disease site following the use of unmodified material containing the live virus. Arch Dermatol 1956; 73: 70–1
Schiff BL, Kern AB. Multiple smallpox vaccinations in the treatment of recurrent herpes simplex. Postgrad Med 1954; 15: 32–6
Kern AB, Schiff BL. Vaccine therapy in recurrent herpes simplex. Arch Dermatol 1964; 89: 844–5
Kutinova L, Benda R, Kalos Z, et al. Placebo-controlled study with subunit herpes simplex virus vaccine in subjects suffering from frequent herpetic recurrences. Vaccine 1988; 6: 223–8
Stanberry LR, Burke RL, Myers MG. Herpes simplex virus treatment of recurrent genital herpes. J Infect Dis 1988; 156: 156–63
Stanberry LR, Harrison CJ, Bernstein DI, et al. Herpes simplex virus glycoprotein immunotherapy of recurrent genital herpes: factors influencing efficacy. Antiviral Res 1989; 11: 203–14
Ho RJY, Burke RL, Merigan TC. Antigen-presenting liposomes are effective in the treatment of recurrent herpes simplex virus genitalis in guinea pigs. J Virol 1989; 63: 2951–8
Bernstein DI, Harrison CJ, Jenski LJ, et al. Cell-mediated immunologic responses and recurrent genital herpes in the guinea pig. J Immunol 1991; 146: 3571–7
Bernstein DI, Harrison CJ, Tepe E, et al. Effect of imiquimod as an adjuvant for immunotherapy of genital HSV in guinea pigs. Vaccine. In press
Straus SE, Corey L, Burke RL, et al. Placebo-controlled trial of vaccination with recombinant glycoprotein D of herpes simplex virus type 2 for immunotherapy of genital herpes. Lancet 1994; 343: 1460–3
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Bernstein, D.I., Stanberry, L.R. Herpes Vaccine. Clin. Immunother. 2, 325–330 (1994). https://doi.org/10.1007/BF03259492
Published:
Issue Date:
DOI: https://doi.org/10.1007/BF03259492